Catherine E. Chaillan Huntington
AstraZeneca (United Kingdom)(GB)
Publications by Year
Research Areas
IL-33, ST2, and ILC Pathways, Eosinophilic Esophagitis, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Monoclonal and Polyclonal Antibodies Research, Occupational exposure and asthma
Most-Cited Works
- → Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation(2015)262 cited
- → Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction(2023)96 cited
- → The IL-33:ST2 axis is unlikely to play a central fibrogenic role in idiopathic pulmonary fibrosis(2023)15 cited
- → Tozorakimab (MEDI3506): a dual-pharmacology anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction(2023)2 cited
- → OP0110 AZD1163 - FIRST-IN-CLASS ANTI-PAD2/4 BI-SPECIFIC ANTIBODY TO INHIBIT AUTOANTIGEN FORMATION IN RHEUMATOID ARTHRITIS(2024)1 cited